Core Insights - The stock of Yiming Oncology-B (01541) rose over 5%, currently up 5.22% at HKD 11.47, with a trading volume of HKD 40.4765 million [1] Group 1: Nobel Prize Announcement - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms [1] - This innovative research identified the immune system's inhibitory switch, offering transformative therapies for millions suffering from autoimmune diseases and cancer [1] - Regulatory T cells (Treg cells) maintain immune tolerance through the Foxp3 transcription factor, with their dysfunction closely linked to autoimmune diseases and cancer [1] Group 2: Development of Tazlestobart - Yiming Oncology is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] - Tazlestobart works by eliminating Treg cells in the tumor microenvironment to exert its anti-tumor effects [2] - The drug enhances ADCC activity through genetic engineering, targeting specific molecules on Treg cells to modulate their function or quantity, thereby boosting immune responses [2]

Core Viewpoint - The stock of Iminconco-B (01541) has risen over 5% due to increased attention on Treg cell therapy and the active clinical development of Tazlestobart monoclonal antibody [1][2] Group 1: Company Developments - Iminconco-B's stock price increased by 5.22%, reaching 11.47 HKD, with a trading volume of 40.47 million HKD [1] - The company is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] Group 2: Scientific Recognition - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms, which has implications for autoimmune diseases and cancer therapies [1] - The discovery of regulatory T cells (Treg cells) and their mechanisms has provided a theoretical foundation for developing new immunomodulatory drugs [1] Group 3: Product Mechanism - Tazlestobart (IMM27M) is designed to eliminate Treg cells in the tumor microenvironment, enhancing anti-tumor efficacy [2] - The drug utilizes genetic engineering to enhance ADCC activity and targets specific molecules on Treg cells, particularly CTLA-4, to modulate their function or quantity [2]

Group 1 - The stock of I-Mab (01541) increased by over 10%, reaching HKD 7.66 with a trading volume of HKD 40.02 million [1] - I-Mab announced the approval of its clinical trial application for Tazlestobart (IMM27M) in combination with Osimertinib for EGFR-mutant locally advanced or metastatic non-squamous non-small cell lung cancer by the National Medical Products Administration (NMPA) [1] - The company received a second payment of USD 5 million from Axion Bio, bringing the total amount received for the collaboration on IMM2510 and IMM27M to USD 20 million [1] Group 2 - Guoyuan International highlighted I-Mab as a research-driven biotechnology company capable of systematically utilizing both innate and adaptive immunity [2] - I-Mab is developing two CD47×CD20 bispecific antibodies/fusion proteins, with IMM0306 being the first to enter clinical trials, showing an overall response rate (ORR) of 90.9% and a complete response (CR) of 27.3% in an Ib trial with 11 patients [2] - Clinical trials for autoimmune diseases are currently in the Ib phase, with the SLE trial enrolling six patients in the second dose group, showing promising response rates, and data is expected to be released mid-year [2]